Overview

The Effect of Entecavir Consolidation on Post-TDF Treatment Durability

Status:
Not yet recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Clinical relapse occurred much earlier and tended to be more severe after cessation of TDF than ETV. The follow-up interval and intensity would be different between ETV and TDF after discontinuation of therapy. Whether switch therapy from TDF to ETV can modify the pattern of relapse is interesting but unclear. Our hypothesis is that entecavir consolidation on post-TDF treatment patients reduce and delay the clinical relapse effectively. Hence in this proof of concept study we would like to evaluate the effect of 6 months and 12 months of entecavir consolidation on post-TDF treatment durability.
Phase:
Phase 4
Details
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Collaborators:
Chang Gung Memorial Hospital
Changhua Christian Hospital
China Medical University Hospital
Treatments:
Entecavir